Zh Nevrol Psikhiatr
-
Zh Nevrol Psikhiatr · Jan 2012
[Experience in using xeomin in the treatment of arm and hand spasticity in the early rehabilitation phase of stroke].
To reduce arm and hand spasticity, 28 patients in the early rehabilitation phase of ischemic hemisphere stroke received injections of the botulinum toxin A preparation xeomin in the content of complex rehabilitation programs. The following muscles: m. biceps brachii, m. flexor digitorum profundus, m. flexor digitorum superficialis, m. flexor carpi ulnaris, m. flexor carpi radialis were injected according to standard scheme. The total dose of drug was 200U in moderate (2-3 scores on the Ashworth scale) and 300U in marked (3-4 scores on the Ashworth scale) spasticity. ⋯ The treatment was most effective in the group of patients with moderate spasticity. The correlation analysis confirmed that the severity of spasticity increased with the disease duration that reduced rehabilitation efficiency. The treatment with xeomin was safe, no serious side-effects were found.
-
Zh Nevrol Psikhiatr · Jan 2012
[Idiopathic generalized epilepsy in young women: choise of treatment strategy].
We studied 279 women, aged 18-40 years old, with epilepsy. The study included the evaluation of anamnesis, clinical and neurological examination, routine EEG and/or video-EEG-monitoring, MRI of the brain. The period of observation was 6 months - 8 years. ⋯ Adverse events were found in 22 of 63 (34.9%) patients treated with valproates, 9 of 25 (36%) patients treated with topiramate, 5 of 39 (1.8%) patients treated with carbamazepine, 3 of 7 (42.9%) patients treated with levetiracetam and in 2 of 5 (40%) patients treated with lamotrigine. The aggravation of absences with carbamazepine was diagnosed in 2 cases, myoclonic seizures - in 2 cases. Therapeutic strategies of young women with juvenile forms of IGE were described and analyzed.
-
Zh Nevrol Psikhiatr · Jan 2012
[Valdoxan (agomelatine) in combined therapy of moderate and severe non-psychotic depressions].
According to data received from the study VREMYA, the combined therapy of moderate and severe non-psychotic depressions with Valdoxane and antidepressants of other pharmacological groups is effective and doesn't cause serious adverse events. These findings suggested using the indicated combination of antidepressants in treatment of resistant affective disorders.